Evidence map›Paper›PMID 41255652›Full record

ReviewJournal of clinical practice and research2025

Agnostic Biomarkers in Molecular Pathology.

Zeynep Sagnak Yilmaz, Yasemin Cakir, Sibel Demir Kececi, Kemal Kursat Bozkurt, Onur Ertunc, Rafet Gunes Ozturk, Ayca Tan

Abstract readReview
In one paragraph

Review in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zeynep Sagnak YilmazDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.
Yasemin CakirDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.
Sibel Demir KececiDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.
Kemal Kursat BozkurtDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.
Onur ErtuncDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.
Rafet Gunes OzturkDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.
Ayca TanDepartment of Molecular Pathology, Dokuz Eylül University Graduate School of Health Sciences, İzmir, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in molecular techniques have revealed that different molecular mechanisms are responsible for the behavior of cancer cells. Molecular alterations play a critical role in both the differential diagnosis of cancer and in the development of targeted therapies. Studies have identified the same potentially targetable mutations across various tumor types, supporting the emergence of tumor-agnostic therapies. To date, five biomarkers have been approved for tumor-agnostic therapy: microsatellite instability (MSI), neurotrophic tyrosine receptor kinase (

Indexed as

Agnosticbiomarkermicrosatellite instabilityneurotrophic tyrosine receptor kinasetumor mutation burden

Identifiers

PMID41255652
PMCPMC12478668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.